ReviewThe Journal of biological chemistry2020
Toward universal donor blood: Enzymatic conversion of A and B to O type.
Review in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Pooled it
- Engineering the Universal Donor: CRISPR-Mediated Blood Group Antigen Deletion and the Path Toward Truly Universal Red Blood Cells-A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- Enhancing red blood cell compatibility: in vitro hemagglutination prevention using a trispecific triabody as a blocking fragment for blood group antigens.Journal of biological engineering · 2026Article
- Catalyzing Carbohydrate Cleavage: Glycosidases and Their Mechanisms.Chemical reviews · 2026Review
- Immobilized Enzymes for ABO-Independent Blood Cell Transfusions.Chembiochem : a European journal of chemical biology · 2025Article
- Tailor-made red cells: the long road towards blood safety.Haematologica · 2025Article
- Progress in Development of Functional Biological and Synthetic Blood Products to Augment Transfusable Blood Supply in Operational Medicine.Bioengineering (Basel, Switzerland) · 2025Review
- OsAPSE modulates non-covalent interactions between arabinogalactan proteinFrontiers in plant science · 2025Article
- Prevention of Blood Incompatibility Related Hemagglutination: Blocking of Antigen A on Red Blood Cells UsingAntibodies (Basel, Switzerland) · 2024Article
- Red Blood Cell Membrane-Coated Nanoparticles Enable Incompatible Blood Transfusions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Application of microbial enzymes in medicine and industry: current status and future perspectives.Future microbiology · 2024Review
- Red blood cells in biology and translational medicine: natural vehicle inspires new biomedical applications.Theranostics · 2024Review
- Crystal Structure ofJournal of applied glycoscience · 2024Article
- Galectin-9 as a Potential Modulator of Lymphocyte Adhesion to Endothelium via Binding to Blood Group H Glycan.Biomolecules · 2023Article
- Mucin utilization by gut microbiota: recent advances on characterization of key enzymes.Essays in biochemistry · 2023Review
- Turning universal O into rare Bombay type blood.Nature communications · 2023Article
- ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies.iScience · 2023Review
- ABO gene editing for the conversion of blood type A to universal type O in RhClinical and translational medicine · 2022Article
- Molecular advances in microbial α-galactosidases: challenges and prospects.World journal of microbiology & biotechnology · 2022Review
- Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort.Nature genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Transfusion of blood, or more commonly red blood cells (RBCs), is integral to health care systems worldwide but requires careful matching of blood types to avoid serious adverse consequences. Of the four main blood types, A, B, AB, and O, only O can be given to any patient. This universal donor O-type blood is crucial for emergency situations where time or resources for typing are limited, so it is often in short supply. A and B blood differ from the O type in the presence of an additional sugar antigen (GalNAc and Gal, respectively) on the core H-antigen found on O-type RBCs. Thus, conversion of A, B, and AB RBCs to O-type RBCs should be achievable by removal of that sugar with an appropriate glycosidase. The first demonstration of a B-to-O conversion by Goldstein in 1982 required massive amounts of enzyme but enabled proof-of-principle transfusions without adverse effects in humans. New α-galactosidases and α-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.